Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P1SJ | ISIN: GB00BK6JQ137 | Ticker-Symbol: N/A
1-Jahres-Chart  (nicht börsennotiert)
OTAQ PLC Chart 1 Jahr
Dow Jones News
401 Leser
Artikel bewerten:
(2)

OTAQ Plc: Result of Annual General Meeting

Finanznachrichten News

DJ Result of Annual General Meeting

OTAQ Plc (OTAQ) 
Result of Annual General Meeting 
31-Jul-2024 / 11:28 GMT/BST 
=---------------------------------------------------------------------------------------------------------------------- 
OTAQ PLC 
("OTAQ" or the "Company") 
 
Result of Annual General Meeting 
 
OTAQ plc (OTAQ.AQ), the innovative technology company targeting the aquaculture and offshore markets, announces that at 
the Annual General Meeting held earlier today, all resolutions were duly passed. Resolutions 1 to 10 were passed as 
ordinary resolutions and resolutions 11 and 12 were passed as special resolutions. The proxy votes received from 
shareholders in respect of each resolution are set out below. 
 
                                      For       Against 
                                 For                Total   Votes 
                                      (% of  Against (% of  number of Withheld 
                                      votes      votes  votes cast 
                                      cast)      cast) 
       Ordinary resolutions 
       To receive, consider and adopt the Directors' 
1       Report and the Company's Annual Accounts for the  80,951,190 99.98% 20,000 0.02%  80,971,190 Nil 
       financial year ended 31 December 2023 
2       To re-elect Sarah Emily Stoten as a Director of  80,951,190 99.98% 20,000 0.02%  80,971,190 Nil 
       the Company 
3       To re-elect Justine Dowds as a Director of the   80,951,190 99.98% 20,000 0.02%  80,971,190 Nil 
       Company 
4       To re-elect Giles Timothy Clifford as a Director  80,951,190 99.98% 20,000 0.02%  80,971,190 Nil 
       of the Company 
5       To re-elect Philip David Newby as a Director of  80,951,190 99.98% 20,000 0.02%  80,971,190 Nil 
       the Company 
6       To re-elect Adam Reynolds as a Director of the   80,951,190 99.98% 20,000 0.02%  80,971,190 Nil 
       Company 
7       To re-elect Harald Volker Rotsch as a Director of 80,951,190 99.98% 20,000 0.02%  80,971,190 Nil 
       the Company 
       To reappoint Azets Audit Services LLP as the 
       Company's auditors to hold office from the 
8       conclusion of this meeting until the conclusion of 80,971,190 100.00% Nil   Nil   80,971,190 Nil 
       the next general meeting at which accounts are 
       laid before the Company 
9       To authorise the Directors to determine the    80,951,190 99.98% 20,000 0.02%  80,971,190 Nil 
       remuneration of the auditors 
       To empower the Directors to allot securities up to 
10      an aggregate nominal amount of GBP428,019.72     80,951,190 99.98% 20,000 0.02%  80,971,190 Nil 
       pursuant to the authority given under section 551 
       of the Companies Act 2006 (the "Act") 
       Special resolutions 
       To approve the general disapplication of 
       pre-emption rights, up to an aggregate nominal 
11      amount of GBP128,405.92 pursuant to the authority  80,951,190 99.98% 20,000 0.02%  80,971,190 Nil 
       given in accordance with section 551 of the Act, 
       as if section 561 of the Act did not apply to the 
       allotment 
       To approve the specific disapplication of 
       pre-emption rights, up to a further aggregate 
12      nominal amount of GBP128,405.92 pursuant to the   80,951,190 99.98% 20,000 0.02%  80,971,190 Nil 
       authority given in accordance with section 551 of 
       the Act, as if section 561 of the Act did not 
       apply to the allotment 

Please note a 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' and 'against' a resolution or the total number of votes cast.

Enquiries

OTAQ PLC                      +44 (0) 1524 748028 
Adam Reynolds, Non-Executive Chairman 
Phil Newby, Chief Executive Officer 
 
Justine Dowds, Chief Financial Officer 
 
Dowgate Capital Limited - AQSE Corporate Advisor & Broker +44 (0)20 3903 7715 
David Poutney / James Serjeant 
 
Nicholas Chambers / Russell Cook 
 
                          +44 (0)20 7933 8780 
Walbrook PR Limited - PR 
                          07971221972 or 07748325236 
Tom Cooper / Nick Rome               OTAQ@walbrookpr.com 
 

About OTAQ

OTAQ is a highly innovative technology company targeting the aquaculture and offshore markets. It already has a number of established products in its portfolio and is focused on further developing its presence, customer base and cross selling opportunities within core markets both organically and via acquisition.

OTAQ's aquaculture products, which include a sonar device (developed for Minnowtech LLC) to scan shrimp in ponds and water quality monitoring, are focused on maximising welfare and production yields. Additionally, the Company is developing a potentially game changing live plankton analysis product for finfish and shellfish farmers. It also continues to target opportunities in the acoustic deterrent devices market via its Sealfence product, which is used by salmon farmers, with global opportunities in Chile, Australia, Canada and Norway.

OTAQ's offshore product range includes OceanSense subsea leak detection, Eagle IP camera systems, Lander seabed survey devices and Subsea electrical connectors and penetrators. It is targeting a number of growth opportunities in new territories and has a strong client base including Expro, Amphenol and National Oilwell Varco. The Company is also focused on the development of new products through this division, with the aim of increased cross-deployment of skills and technologies into the aquaculture arena.

The Company is also developing high accuracy location trackers for specialist applications. Having already added clients within safety and multiple participant sport/racing applications, the Company is investigating wider market potential - including opportunities in the seafood industry.

----------------------------------------------------------------------------------------------------------------------- Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

ISIN:     GB00BK6JQ137 
Category Code: RAG 
TIDM:     OTAQ 
LEI Code:   213800CZGMYB5XTUXJ52 
Sequence No.: 337729 
EQS News ID:  1958223 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1958223&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

July 31, 2024 06:29 ET (10:29 GMT)

© 2024 Dow Jones News
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.